Pfizer

Bengaluru: Pfizer said on Wednesday it had struck an exclusive licensing agreement with China's Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases, in a deal worth up to USD 2.6 billion.

The deal marks another bet on a Chinese biotech by the pharma major as it seeks to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue.

Pfizer will pay Starna $330 million upfront and could pay up to $2.3 billion more if the treatments meet development, regulatory and sales milestones. The therapies have not yet entered human trials.

Starna would also receive royalties on sales of any approved products.

The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities.

In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body, allowing them to target and eliminate disease-causing immune cells.

By contrast, conventional CAR-T treatments involve the complex process of collecting and re-engineering a patient’s cells outside the body before reinfusing them.

The deal follows Pfizer’s $10.5 billion agreement with Innovent Biologics in May and an earlier deal with China’s 3SBio in 2025.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .